Lupin Settles Mirabegron Patent Dispute With Astellas for USD 90 Million, Clears US Sales
Under the agreement, Lupin and its U.S. unit will pay Astellas a USD 75 million upfront payment and per-unit licensing fees on Mirabegron sales through September 2027, the company said in an exchange filing.
Written By : sheeba farhat
Published On 2026-02-10 14:30 GMT | Update On 2026-02-10 14:41 GMT
Advertisement
Mumbai: Indian drugmaker Lupin, opens new tab said on Tuesday it agreed to a USD 90 million settlement with Japan's Astellas Pharma (4503.T), opens new tab in a patent dispute over the bladder disorder drug Mirabegron, a move that allows it to continue selling the product in the United States.
Under the agreement, Lupin and its U.S. unit will pay Astellas a $75 million upfront payment and per-unit licensing fees on Mirabegron sales through September 2027, the company said in an exchange filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.